A role for cyclooxygenase II inhibitors in modulating temporomandibular joint inflammation from a meal pattern analysis perspective

Journal of Oral and Maxillofacial Surgery

Volumn 62, Issue 8, 2004, Pages 989-995

  Kerins, Carolyn ^a   Carlson, David ^a   McIntosh, James ^a   Bellinger, Larry ^a,b  

^a TEXAS AANDM UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; FREUND ADJUVANT; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEEDING BEHAVIOR; FOOD INTAKE; INFLAMMATION; MALE; MYOFASCIAL PAIN; NONHUMAN; RAT; TEMPOROMANDIBULAR JOINT DISORDER;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; FEEDING BEHAVIOR; FREUND'S ADJUVANT; INJECTIONS, INTRA-ARTICULAR; INTERLEUKIN-1; ISOENZYMES; LACTONES; MALE; PEROXIDASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC; SULFONES; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT DISORDERS; TIME FACTORS;

EID: 3242692651     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2003.09.016     Document Type: Article

References (37)

1. Stohler C.S., Ashton-Miller J.A., Carlson D.S. The effects of pain from the mandibular joint and muscles on masticatory motor behavior in man. Arch Oral Biol. 33:1988;175
2. Sessle B.J., Hu J.W. Mechanisms of pain arising from articular tissues. Can J Physiol Pharmacol. 69:1991;617
3. Sessle B.J. Neural mechanisms and pathways in craniofacial pain. Can J Neurol Sci. 26:(suppl 3):1999;S7
4. Sessle B.J. The neural basis of temporomandibular joint and masticatory muscle pain. J Orofac Pain. 13:1999;238
5. Crofford L.J., Wilder R.L., Ristimaki A.P., et al. Cyclooxygenase 1 and 2 expression in rheumatoid synovial tissues Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest. 93:1994;1095
6. Bucala R., Ritchlin C., Winchester R., et al. Constituitive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med. 173:1991;569
7. Sarlis N.J., Chowdrey H.S., Stephanou A., et al. Chronic activation of the hypothalamopituitary-adrenal axis and loss of circadian rhythm during adjuvant-induced arthritis in the rat. Endocrinology. 130:1992;1775
8. Selgas L., Arce A., Esquifino A.L., et al. Twenty-four-hour rhythms of serum ACTH, prolactin, growth hormone, and thyroid-stimulating hormone, and of median-eminence norepinephrine, dopamine and serotonin in rats injected with Freund's adjuvant. Chronobiol Int. 14:1997;253
9. Mazzier A.G., Laskin D.M., Catchpole H.R. Adjuvant induced arthritis in the temporomandibular joint of the rat. Arch Pathol Lab Med. 83:1967;543
10. Sano H., Hla T., Maier J.A.M., et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest. 89:1992;97
11. Dayer J.M., Krane S.M., Russell R.G.G., et al. Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci U S A. 73:1976;945
12. Shingu M., Isayama T., Yasutake C., et al. Role of oxygen radicals and IL-6 in IL-1-dependent cartilage matrix degradation. Inflammation. 18:1994;613
13. Serhan C.N., Ward P.A. Molecular and Cellular Basis of Inflammation. 1999;295-296 Humana Press, Totoaw, NH
14. Hasty K.A., Reife R.A., Karg A.H. The role of stromelysin in cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum. 33:1992;388
15. Firestein G.S., Paine M.M. Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. Am J Pathol. 140:1992;1309
16. Okada Y., Shinmei M., Tanaka O., et al. Localization of matrix mettalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest. 66:1992;680
17. Kubota E., Kubota T., Matsumoto J., et al. Synovial fluid cytokines and proteinases as markers of temporomandibular joint disease. J Oral Maxillofac Surg. 56:1998;192
18. Harper R.P., Kerins C.A., Talwar R., et al. Meal pattern analysis in response to temporomandibular joint inflammation in the rat. J Dent Res. 79:2000;1704
19. Kerins C.A., Carlson D.S., McIntosh J.E., et al. Meal pattern changes associated with temporomandibular joint inflammation/pain in rats; analgesic effects. Pharm Biochem Behav. 75:2003;181
20. Bellinger L.L., Mendel V.E. Blood profile and balance study of rats given the putative anorectic agent satietin. Am J Physiol. 268:1995;R1
21. Bellinger L.L., Williams F.E. Meal patterns and plasma liver enzymes and metabolites after total liver denervations. Physiol Behav. 58:1995;625
22. Bellinger L.L., Fabia R., Husberg B.S. Meal patterns prior to and following liver transplantation in rats. Physiol Behav. 62:1997;525
23. Clifton P.G. Meal patterning in rodents Psychopharmacological and neuro-anatomical studies. Neurosci Biobehav Rev. 24:2000;213
24. Harper R.P., Brown C.M., Triplett M.M., et al. Masticatory function in patients with juvenile rheumatoid arthritis. Pediatr Dent. 22:2000;200
25. Lund J.P., Donga R., Widmer C.G., et al. The pain-adaptation model A discussion of the relationship between chronic musculoskeletal pain and motor activity. Can J Physiol Pharm. 69:1991;683
26. Harper R.P., Kerins C.A., McIntosh J.E., et al. Modulation of the inflammatory response in the rat TMJ with increasing doses of complete Freund's adjuvant. Osteoarthritis Cartilage. 9:2001;619
27. Carleson J., Bileviciute I., Theodorsson E., et al. Effects of adjuvant on neuropeptide-like immunoreactivity in the temporomandibular joint and trigeminal ganglia. J Orofac Pain. 11:1997;195
28. Hutchins B., Spears R., Hinton R.J., et al. Calcitonin gene-related peptide and substance P immunoreactivity in rat trigeminal ganglia and brainstem following adjuvant-induced inflammation of the temporomandibular joint. Arch Oral Biol. 45:2000;335
29. Kang R.Y., Freire-Moar J., Sigal E., et al. Expression of cyclooxygenase-2 in humans and an animal model of rheumatoid arthritis. Br J Rheum. 35:1996;711
30. Francischi J.N., Chaves C.T., Moura A.C.L., et al. Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharm. 137:2002;837
31. Chan C.C., Boyce S., Brideau C., et al. Rofecoxib [Rofecoxib, MK-0966; 4-(4′methylsulfonylphenyl)-3-phenyl-2-(5h)-furanone] A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 290:1999;551
32. Dray A. Inflammatory mediators of pain. Br J Anaesth. 75:1995;125
33. Anderson G.D., Hauser S.D., McGarity K.L., et al. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 97:1996;2672
34. Masferrer J.L., Zweifel B.S., Manning P.T., et al. Selective inhibition of inducible cyclooxygenase-2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci U S A. 91:1994;3228
35. Saag K., Fisher C., McKay J., et al. MK-0966 a specific COX-2 inhibitor has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6 week controlled clinical trial. Arthritis Rheum. 41:1998;S196. (abstr)
36. Cannon G., Caldwell J., Holt P., et al. MK-0966, a specific COX-2 inhibitor has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26 week controlled clinical trial. Arthritis Rheum. 41:1998;S196. (abstr)
37. Ehrich E.W., Dallob A., DeLepeleire I., et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 65:1999;336